A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

Conditions: Breast Cancer, Adjuvant Therapy, HER2-positive Breast Cancer

Sex: All

Ages: 18 Years – N/A

Enrollment: 130

Sponsor: Pierre Fabre Medicament

Location: Belgium

Summary

The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in Europe.

Eligibility Criteria

Inclusion Criteria:Patients will be eligible for inclusion if they fulfill all of the following criteria:Age ≥ 18 years at neratinib treatment initiationHaving received at least one initial dose of neratinib as an extended adjuvant therapy for the treatment of early-stage HER2+ breast cancer, in the context of the EAP in Europe, and between August 01, 2017 and December 31, 2020Patients (or next of kin/legal representative, if applicable) who provide written informed consent or non-opposition.Exclusion Criteria:N/A

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05599334). StuddyBuddy aggregates publicly available trial information.